SCHEMBL14045950

SCHEMBL14045950

C/N=C(\c1ccccc1)c1ccccc1C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
ALOX15 P16050 1/20 0.56
AKR1C3 P42330 3/20 0.55
POLB P06746 2/20 0.47
NAPRT Q6XQN6 2/20 0.44
DAO P14920 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
CDC25B P30305 2/20 0.44
CDC25A P30304 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ATM Q13315 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862271 0.78 ALDH1A1 (0.45) ALDH1A1NAPRTDAOTSHRSMN1; SMN2
Phthalic Acid SCHEMBL11784201 0.78 ALDH1A1 (0.93) ALDH1A1ALOX15AKR1C3POLBNAPRT
SCHEMBL24556547 0.77 MAPT (0.47) ALDH1A1AKR1C3POLBSMN1; SMN2KMT2A
Phthalic Acid SCHEMBL30665138 0.75 TSHR (0.78) ALDH1A1ALOX15AKR1C3POLBNAPRT
Phthalic Acid SCHEMBL4578569 0.75 TSHR (0.78) ALDH1A1ALOX15AKR1C3POLBNAPRT
Phthalic Acid SCHEMBL322997 0.75 TSHR (0.78) ALDH1A1ALOX15AKR1C3POLBNAPRT
SCHEMBL18793082 0.75 ALDH1A1 (0.61) ALDH1A1ALOX15AKR1C3POLBNAPRT
Phthalic Acid SCHEMBL30575217 0.75 ALDH1A1 (0.88) ALDH1A1ALOX15AKR1C3POLBNAPRT
Phthalic Acid SCHEMBL4396104 0.75 ALDH1A1 (0.88) ALDH1A1ALOX15AKR1C3POLBNAPRT
Phthalic Acid SCHEMBL4797005 0.75 ALDH1A1 (0.88) ALDH1A1ALOX15AKR1C3POLBNAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367038-B2 Blocking or activation of endogenous proteins variations rncoded by mutated gees HMI Medical Innovations, LLC (US) 2013-02-05 US disclosed
US-20080269262-A1 Blocking or activation of endogenous proteins variations rncoded by mutated gees HMI MEDICAL INNOVATIONS, LLC. 2008-10-30 US disclosed
WO-2007037898-A2 THERAMUTEIN MODULATORS HOUSEY PHARMACEUTICALS INC (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269262-A1 Blocking or activation of endogenous proteins variations rncoded by mutated gees SERBP1, SERPINA6, UBE2V1 ALDH1A1 3621/4885ALOX15 4695/4885AKR1C3 4126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.